A Phase Ib Study of Selumetinib in Patients with Previously Treated or Untreated Advanced/Metastatic NSCLC Who are Receiving Standard Chemotherapy Regimens
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Selumetinib (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 10 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Aug 2017.
- 10 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.